SCHEMBL17554134

SCHEMBL17554134

COc1cccc(C(=O)Nc2c(OC)cccc2C(=O)NCCN2CCOCC2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.74
CYP2C19 P33261 2/20 0.74
BCL3 P20749 2/20 0.71
LMNA P02545 1/20 0.64
ALDH1A1 P00352 3/20 0.61
GAA P10253 1/20 0.61
DRD4 P21917 8/20 0.59
DRD2 P14416 4/20 0.59
KDM4E B2RXH2 2/20 0.56
TP53 P04637 1/20 0.56
POLB P06746 1/20 0.56
ALOX15 P16050 1/20 0.56
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 2/20 0.55
CYP2D6 P10635 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
MAPT P10636 1/20 0.55
PMP22 Q01453 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554024 0.91 ALDH1A1 (0.74) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL17554016 0.90 BCL3 (0.75) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL17554070 0.89 LMNA (0.80) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL30560634 0.89 LMNA (0.80) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL16431097 0.87 ALDH1A1 (0.80) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL17554156 0.87 BCL3 (0.79) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL29849812 0.87 ALDH1A1 (0.80) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL17554113 0.86 BCL3 (0.85) CYP2C9CYP2C19BCL3LMNAALDH1A1
SCHEMBL30098940 0.86 CYP2C19 (1.00) CYP2C9CYP2C19LMNAALDH1A1DRD4
SCHEMBL15822962 0.86 CYP2C19 (1.00) CYP2C9CYP2C19LMNAALDH1A1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
EP-3174602-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2017-06-07 EP disclosed
WO-2016016728-A2 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248756-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 CYP2C9 898/4885CYP2C19 1286/4885BCL3 1/4885
US-10273218-B2 BCL-3 inhibitors BCL3, BCL2, BCL2L13 CYP2C9 1015/4885CYP2C19 1536/4885BCL3 1/4885
US-20170267653-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 CYP2C9 1015/4885CYP2C19 1536/4885BCL3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.